UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (18), p.1829

2021

Volltextzugriff (PDF)

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Pigment cell and melanoma research, 2018-07, Vol.31 (4), p.516-522

2018

Volltextzugriff (PDF)

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

Cancer research (Chicago, Ill.), 2008-08, Vol.68 (16), p.6507-6515

2008

Volltextzugriff (PDF)

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Journal of translational medicine, 2017-06, Vol.15 (1), p.146-9, Article 146

2017

Volltextzugriff (PDF)

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1248-1260

2016

Volltextzugriff (PDF)

Communities for Healthy Living (CHL) A Community-based Intervention to Prevent Obesity in Low-Income Preschool Children: Process Evaluation Protocol

Trials, 2020-07, Vol.21 (1), p.674-13, Article 674

2020

Volltextzugriff (PDF)

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling

Oncogene, 2017-07, Vol.36 (30), p.4235-4242

2017

Volltextzugriff (PDF)

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Journal of medicinal chemistry, 2021-12, Vol.64 (23), p.17146-17183

2021

Volltextzugriff (PDF)

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Cell chemical biology, 2020-01, Vol.27 (1), p.41-46.e17

2020

Volltextzugriff (PDF)

Efficacy and Safety of Onartuzumab in Combination with First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer

Clinical lung cancer, 2017-01, Vol.18 (1), p.50-59

2017

Volltextzugriff (PDF)

Efficacy of Transthoracic Echocardiography for Diagnosing Heart Failure in Septic Shock

The American journal of the medical sciences, 2014-04, Vol.347 (4), p.295-298

2014

Volltextzugriff (PDF)

Evaluation of a cluster-randomized controlled trial: Communities for Healthy Living, family-centered obesity prevention program for Head Start parents and children

The international journal of behavioral nutrition and physical activity, 2023-01, Vol.20 (1), p.4-4, Article 4

2023

Volltextzugriff (PDF)

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Clinical cancer research, 2019-06, Vol.25 (11), p.3239-3246

2019

Volltextzugriff (PDF)

Metabolic syndrome prevalence and associations in a bariatric surgery cohort from the Longitudinal Assessment of Bariatric Surgery-2 study

Metabolic syndrome and related disorders, 2014-03, Vol.12 (2), p.86

2014

Volltextzugriff (PDF)

Modeling initiation of Ewing sarcoma in human neural crest cells

PloS one, 2011-04, Vol.6 (4), p.e19305-e19305

2011

Volltextzugriff (PDF)

Outcome-Driven Cluster Analysis with Application to Microarray Data

PloS one, 2015-11, Vol.10 (11), p.e0141874-e0141874

2015

Volltextzugriff (PDF)

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2017-03, Vol.22 (3), p.264-271

2017

Volltextzugriff (PDF)

Potential interference by antineutrophil cytoplasmic autoantibodies in myeloperoxidase immunoassays

Clinical chemistry (Baltimore, Md.), 2008-12, Vol.54 (12), p.2084-2086

2008

Volltextzugriff (PDF)

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-05, Vol.17 (5), p.697-707

2015

Volltextzugriff (PDF)

Principle component analysis and its variants for biometrics

Proceedings. International Conference on Image Processing, 2002, Vol.1, p.I-I

2002

Volltextzugriff (PDF)

Process measure aimed at reducing time to haemorrhage control: outcomes associated with Code Crimson activation in exsanguinating truncal trauma

ANZ journal of surgery, 2020-04, Vol.90 (4), p.481-485

2020

Volltextzugriff (PDF)

Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting

Biology of blood and marrow transplantation, 2011-07, Vol.17 (7), p.943-955

2011

Volltextzugriff (PDF)

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

PloS one, 2015-10, Vol.10 (10), p.e0139679

2015

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)
Tagungsberichte
(1)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(18)
Female
(9)
Male
(9)
Oncology
(8)
Aged
(7)
Middle Aged
(7)
Adult
(6)
Melanoma - Drug Therapy
(5)
Mutation
(5)
Proto-Oncogene Proteins B-Raf - Genetics
(5)
Aged, 80 And Over
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Melanoma - Genetics
(4)
Tumors
(4)
Animals
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Azetidines - Administration & Dosage
(3)
Cancer
(3)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Communities for Healthy Living (CHL) A Community-based Intervention to Prevent Obesity in Low-Income Preschool Children: Process Evaluation Protocol

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Efficacy and Safety of Onartuzumab in Combination with First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer

Efficacy of Transthoracic Echocardiography for Diagnosing Heart Failure in Septic Shock

Evaluation of a cluster-randomized controlled trial: Communities for Healthy Living, family-centered obesity prevention program for Head Start parents and children

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Metabolic syndrome prevalence and associations in a bariatric surgery cohort from the Longitudinal Assessment of Bariatric Surgery-2 study

Modeling initiation of Ewing sarcoma in human neural crest cells

Outcome-Driven Cluster Analysis with Application to Microarray Data

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

Potential interference by antineutrophil cytoplasmic autoantibodies in myeloperoxidase immunoassays

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

Principle component analysis and its variants for biometrics

Process measure aimed at reducing time to haemorrhage control: outcomes associated with Code Crimson activation in exsanguinating truncal trauma

Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

Aktive Filter

Suchergebnisse filtern